Tolterodine (Detrol®, Detrol® LA) Indications and Dosage
- overactive bladder (OAB)
- urinary incontinence
- urinary urgency
Tolterodine (Detrol®, Detrol® LA) Indications and Dosage
For the treatment of an overactive bladder (OAB) with symptoms of urinary frequency, urinary urgency, or urge-related urinary incontinence:
Oral dosage (immediate-release tablets):
Adults, including the elderly: 2 mg PO twice daily. The dose may be lowered to 1 mg PO twice daily based on individual response and tolerability. If significant renal or hepatic disease is present or if concurrently taking CYP3A4-inhibiting drugs, reduce to 1 mg PO twice daily.
Children: Safe and effective use has not been established.
Oral dosage (extended-release capsules):
Adults, including the elderly: 4 mg PO once daily. The dose may be lowered depending on individual response or tolerability. If significant renal or hepatic disease is present or if concurrently taking CYP3A4-inhibiting drugs, reduce to 2 mg PO once daily.
Children: Not recommended. According to the manufacturer, efficacy has not been demonstrated during controlled trials.
Maximum Dosage Limits:
- Adults: 4 mg/day PO.
- Elderly: 4 mg/day PO.
- Adolescents: Safe and effective use has not been established.
- Children: Safe and effective use has not been established.
Patients with hepatic impairment:
Reduce dosage by 50% to 1 mg PO twice daily, or, if using extended-release capsules, to 2 mg PO once daily.
Patients with renal impairment:
CrCl > 30 ml/min: Follow initial dosage guidelines; adjust based on response and tolerance.
CrCl <= 30 ml/min: Reduce dosage by 50% to 1 mg PO twice daily, or, if using extended-release capsules, to 2 mg PO once daily.
† non-FDA-approved indication
[ Last revised: 7/6/2004 10:18:00 AM ]
Related entries
Syndicate
|
